# Prevention of Contrast Induced Nephropathy by Erythropoietin

> **NCT01364402** · PHASE3 · UNKNOWN · sponsor: **Western Galilee Hospital-Nahariya** · enrollment: 142 (estimated)

## Conditions studied

- Diabetes
- Chronic Kidney Insufficiency

## Interventions

- **DRUG:** Epoetin beta
- **DRUG:** Saline 0.9%

## Key facts

- **NCT ID:** NCT01364402
- **Lead sponsor:** Western Galilee Hospital-Nahariya
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-08
- **Primary completion:** 2013-08
- **Final completion:** 2013-12
- **Target enrollment:** 142 (ESTIMATED)
- **Last updated:** 2012-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01364402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01364402, "Prevention of Contrast Induced Nephropathy by Erythropoietin". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01364402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*